MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic-Exatecan
Modify Date: 2025-09-02 12:38:14
MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic-Exatecan structure
|
Common Name | MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic-Exatecan | ||
|---|---|---|---|---|
| CAS Number | 2414393-22-7 | Molecular Weight | 1074.12 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C55H60FN9O13 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic-ExatecanMC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic-Exatecan is a drug-linker conjugate for ADC, contains the ADC linker (MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic acid) and a DNA topoisomerase I inhibitor Exatecan (HY-13631). MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic-Exatecan synthesized ADC can be used in study of cancer[1]. |
| Name | MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic-Exatecan |
|---|
| Description | MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic-Exatecan is a drug-linker conjugate for ADC, contains the ADC linker (MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic acid) and a DNA topoisomerase I inhibitor Exatecan (HY-13631). MC-Gly-Gly-Phe-Gly-Cyclobutanecarboxylic-Exatecan synthesized ADC can be used in study of cancer[1]. |
|---|---|
| Related Catalog | |
| Target |
Camptothecins |
| References |
[1]. HUA Haiqing, et al. Antibody-drug conjugate and medical use thereof. Patent WO2021190564A1. |
| Molecular Formula | C55H60FN9O13 |
|---|---|
| Molecular Weight | 1074.12 |
| InChIKey | DBCVGCVTFAJVMD-HKMBIKTJSA-N |
| SMILES | CCC1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1cc(F)c(C)c3c1c2C(NC(=O)C1(OCNC(=O)CNC(=O)C(Cc2ccccc2)NC(=O)CNC(=O)CNC(=O)CCCCCN2C(=O)C=CC2=O)CCC1)CC3 |